(News Bulletin 247) – AstraZeneca announced on Thursday that one of its star immunotherapies, Imfinzi, had succeeded in improving the survival of patients suffering from a form of lung cancer whose tumor is operable.

- Advertisement -

This phase III trial established that treatment with Imfinzi, before and after surgery, ‘significantly’ increased event-free survival (i.e. without recurrence or progression of the disease) in patients with non-small cell cancer.

‘Patients with non-small cell cancer face unacceptably high rates of disease recurrence, despite chemotherapy treatment and surgery,’ says branch head Susan Galbraith. oncology from AstraZeneca.

- Advertisement -

“We have demonstrated that the addition of Imfinzi, both before and after surgery, significantly improves patient survival without disease recurrence or progression,” she added.

Listed on the London Stock Exchange, AstraZeneca shares were up 0.4% on Thursday mid-morning following this announcement.

Copyright (c) 2023 News Bulletin 247. All rights reserved.